Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Garufi C, Bochicchio A, Rosati G, Aprile G, Giaquinta S, Torri V, Bardelli A, Gion M, Martoni A. Pinto C, et al. Among authors: gion m. Ann Oncol. 2011 Nov;22(11):2424-2430. doi: 10.1093/annonc/mdq782. Epub 2011 Mar 8. Ann Oncol. 2011. PMID: 21385884 Free article. Clinical Trial.
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D. Gasparini G, et al. Among authors: gion m. Breast Cancer Res Treat. 2007 Mar;101(3):355-65. doi: 10.1007/s10549-006-9306-9. Epub 2006 Jul 19. Breast Cancer Res Treat. 2007. PMID: 16850247 Clinical Trial.
Appropriateness of the use of clinical and radiologic examinations and laboratory tests in the follow-up of surgically-treated breast cancer patients. Results of the Working Group on the Clinical Aspects of Follow-up.
Boccardo F, Bruzzi P, Cionini L, Confalonieri C, Fossati R, Gion M, Giuseppetti GM, Paradiso A, Parma E, Racanelli A, et al. Boccardo F, et al. Among authors: gion m. Ann Oncol. 1995;6 Suppl 2:57-9. doi: 10.1093/annonc/6.suppl_2.s57. Ann Oncol. 1995. PMID: 8547200
Free DNA in urine: a new marker for bladder cancer? Preliminary data.
Zancan M, Franceschini R, Mimmo C, Vianello M, Di Tonno F, Mazzariol C, Malossini G, Gion M. Zancan M, et al. Among authors: gion m. Int J Biol Markers. 2005 Apr-Jun;20(2):134-6. doi: 10.1177/172460080502000209. Int J Biol Markers. 2005. PMID: 16011045 Free article.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Among authors: gion m. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.
244 results